Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 2/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.48 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.41 |
| ▸ | SHBG | P04278 | 2/20 | 0.41 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497527 | 0.82 | G6PD (0.46) | G6PDCYP19A1GPBAR1SHBGNR3C1 | |
| SCHEMBL5488565 | 0.82 | G6PD (0.46) | G6PDCYP19A1GPBAR1SHBGNR3C1 | |
| SCHEMBL11518397 | 0.81 | CYP19A1 (0.64) | G6PDCYP19A1AKR1B10AKR1B1OR51E2 | |
| SCHEMBL4585718 | 0.81 | CYP19A1 (0.64) | G6PDCYP19A1AKR1B10AKR1B1OR51E2 | |
| SCHEMBL6254375 | 0.81 | CYP19A1 (0.64) | G6PDCYP19A1AKR1B10AKR1B1OR51E2 | |
| SCHEMBL10301245 | 0.80 | CYP19A1 (0.65) | G6PDCYP19A1GPBAR1SHBGSERPINA6 | |
| SCHEMBL497888 | 0.79 | GPBAR1 (0.43) | G6PDCYP19A1GPBAR1SHBGSERPINA6 | |
| SCHEMBL6446959 | 0.79 | GPBAR1 (0.43) | G6PDCYP19A1GPBAR1SHBGSERPINA6 | |
| SCHEMBL6434159 | 0.79 | GPBAR1 (0.43) | G6PDCYP19A1GPBAR1SHBGSERPINA6 | |
| SCHEMBL11516238 | 0.78 | GPBAR1 (0.59) | CYP19A1GPBAR1SHBGSERPINA6CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | BIOVIE INC. | 2012-04-26 | — | — | US | disclosed |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | BIOVIE INC. | 2012-02-16 | — | — | US | disclosed |
| US-8106036-B2 | Pharmaceutical compositions-4 | HARBOR BIOSCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-8022234-B2 | Compounds and compositions | HARBOR BIOSCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | FRINCKE JAMES M | 2011-09-08 | — | — | US | disclosed |
| US-7947846-B2 | 15-OXA-steroid compounds | HARBOR BIOSCIENCES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110009372-A1 | Compounds and compositions | BIOVIE INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| EP-1422234-A2 | Immunomodulatory steroids, in particular the hemihydrate of 16.alpha.-bromoepiandrosterone | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | BIOVIE INC. | 2004-05-20 | — | — | US | disclosed |
| US-20040043973-A1 | Pharmaceutical compositions and treatment methods | BIOVIE INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1372664-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | Hollis-Eden Pharmaceuticals Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-6667299-B1 | 16-alpha-bromo-3-beta-hydroxy-5-alpha-androstan-17-one hemihydrate; 16-alpha-bromoepiandrosterone; steroid; immune modulator | HOLLIS-EDEN PHARMACEUTICALS, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030083231-A1 | Blood cell deficiency treatment method | BIOVIE INC. | 2003-05-01 | — | — | US | disclosed |
| US-20030060425-A1 | Immune modulation method using steroid compounds | BIOVIE INC. | 2003-03-27 | — | — | US | disclosed |
| WO-2002069977-A1 | USE OF CERTAIN STEROIDS FOR TREATMENT OF BLOOD CELL DEFICIENCIES | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| EP-1163256-A1 | HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | Hollis-Eden Pharmaceuticals Inc. (US) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000056757-A1 | IMMUNOMODULATORY STEROIDS, IN PARTICULAR THE HEMIHYDRATE OF 16.ALPHA.-BROMOEPIANDROSTERONE | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009372-A1 | Compounds and compositions | HSD3B1, CYP17A1, HSD17B1 | G6PD 646/4885CYP19A1 28/4885AKR1B10 192/4885 |
| US-20030060425-A1 | Immune modulation method using steroid compounds | HSD3B1, NR5A1, HSD17B1 | G6PD 769/4885CYP19A1 32/4885AKR1B10 211/4885 |
| US-20030083231-A1 | Blood cell deficiency treatment method | THPO, HPGDS, MPL | G6PD 13/4885CYP19A1 21/4885AKR1B10 920/4885 |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | MPL, THPO, HSD3B2 | G6PD 71/4885CYP19A1 13/4885AKR1B10 1145/4885 |
| US-20040097406-A1 | Pharmaceutical compositions and treatment methods - 4 | HSD3B1, IL4, HSD17B7 | G6PD 526/4885CYP19A1 37/4885AKR1B10 284/4885 |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | HSD3B1, HSD3B2, HSD17B7 | G6PD 559/4885CYP19A1 33/4885AKR1B10 264/4885 |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | G6PD 105/4885CYP19A1 13/4885AKR1B10 696/4885 |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | CYP51A1, HSD11B1, HSD3B1 | G6PD 1176/4885CYP19A1 27/4885AKR1B10 571/4885 |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | G6PD 105/4885CYP19A1 13/4885AKR1B10 696/4885 |
| US-20040043973-A1 | Pharmaceutical compositions and treatment methods | HSD17B1, HSD17B7, HSD17B3 | G6PD 476/4885CYP19A1 30/4885AKR1B10 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.